EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Periadventitial delivery of mesenchymal stem cells improves vascular remodeling and maturation in arteriovenous fistulas

Sreenivasulu Kilari iD, Randall R DeMartino iD, Scott L Nyberg iD, Patrick G Dean, Jill J Colglazier, Edwin Takahashi iD, Gaurav Baranwal iD, Prabh G Singh iD, Jamie Kane iD, Katrin Nitz iD, Esther Lutgens iD, John J Dillon iD und 5 weitere

Science Translational Medicine · 2025

DOI: 10.1126/scitranslmed.adp7723 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Sreenivasulu Kilari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Arteriovenous Fistula, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Vascular Remodeling. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Worldwide, more than 4 million patients with end-stage kidney disease require hemodialysis through an arteriovenous fistula (AVF). AVFs fail because of venous neointimal hyperplasia (VNH) resulting in venous stenosis formation. A phase 1 randomized trial in patients undergoing upper extremity AVF placement was performed to evaluate the safety and efficacy of autologous adipose–derived mesenchymal stem cells (MSCs) in improving AVF function. The mechanism of action by which MSCs exert their beneficial effects was investigated using AVFs created in mice and pigs treated with allogenic MSCs and xenotransplant using patient MSCs in CD1- Foxn1nu mice. At a median follow-up of 42 months, patients with MSC-treated AVFs had reduced time to maturation with an increase in the vein diameter compared with controls. AVFs treated with allogenic MSCs in mice and pigs had an increase in M2- and M1-like macrophages with a decrease in VNH. Transcriptomic analysis of AVFs treated with allogenic MSCs in mouse and MSC xenotransplants of patients with successful AVFs showed decreased peroxisome proliferator–activated receptor gamma ( Ppar γ) and leptin receptor ( Lepr ) and increased latent transforming growth factor–beta–binding protein 2 ( Ltbp2 ). PPARγ was reduced in CD68 (+) cells from successful AVFs and allogenic MSC-treated mouse AVFs. Venous stenosis and VNH formation were mitigated in AVFs of mice with Ppar γ ablation in immune cells. Conditioned medium from MSCs of responders versus nonresponders had decreased proinflammatory genes, senescence-associated proteins, and monocyte-to-macrophage differentiation induced by phorbol 12-myristate-13-acetate. Periadventitial delivery of MSCs to AVFs promoted positive vascular remodeling through decreased inflammatory responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arteriovenous FistulaMesenchymal Stem Cell TransplantationMesenchymal Stem CellsVascular RemodelingAnimalsFemaleHumansMaleMiceMiddle AgedMacrophagesNeointimaPPAR gammaSwine

Substanzen

PPAR gamma

Autor:innen und Institutionen

  • Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
  • Division of Vascular Surgery, Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
  • Transplantation Surgery, Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
  • Division of Vascular and Interventional Radiology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Cardiovascular Medicine and immunology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Sreenivasulu Kilari, Randall R DeMartino, Scott L Nyberg, Edwin Takahashi, Gaurav Baranwal, Prabh G Singh, Jamie Kane, Katrin Nitz, Esther Lutgens, John J Dillon, Jay Mandrekar, Sanjay Misra

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Kilari, S., DeMartino, R. R., Nyberg, S. L., Dean, P. G., Colglazier, J. J., Takahashi, E., Baranwal, G., Singh, P. G., Kane, J., Nitz, K., Lutgens, E., Dillon, J. J., Vazquez-Padron, R. I., Mandrekar, J., Dietz, A. B., Mukhopadhyay, D., & Misra, S. (2025). Periadventitial delivery of mesenchymal stem cells improves vascular remodeling and maturation in arteriovenous fistulas. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adp7723

Vancouver

Kilari S, DeMartino RR, Nyberg SL, Dean PG, Colglazier JJ, Takahashi E, et al. Periadventitial delivery of mesenchymal stem cells improves vascular remodeling and maturation in arteriovenous fistulas. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adp7723

BibTeX
@article{Kilari2025,
  author = {Kilari, Sreenivasulu and DeMartino, Randall R and Nyberg, Scott L and Dean, Patrick G and Colglazier, Jill J and Takahashi, Edwin and Baranwal, Gaurav and Singh, Prabh G and Kane, Jamie and Nitz, Katrin and Lutgens, Esther and Dillon, John J and Vazquez-Padron, Roberto I and Mandrekar, Jay and Dietz, Allan B and Mukhopadhyay, Debabrata and Misra, Sanjay},
  title = {Periadventitial delivery of mesenchymal stem cells improves vascular remodeling and maturation in arteriovenous fistulas},
  journal = {Science Translational Medicine},
  year = {2025},
  doi = {10.1126/scitranslmed.adp7723}
}
Kostenlos starten →